Histotripsy, HistoSonics, and the Next Era of Non-Invasive Surgery. Evidence, Adoption, and the Bigger Medtech Lesson. Keynote: Peter Hebert, Co-Founder of Lux Capital, and Armen Vidian, Co-Founder of Recode Ventures. Why Growth Is Driving Medtech M&A 2026. A Market Defined by Strong Fundamentals and Selective Capital. Medtech M&A 2026: Key Trends Shaping the Next Wave of Medical Device Deals. Medtech Branding Begins With the Define Phase. Medtech Branding: Why Startups Need to Define Their Story Early. Opening Fireside Chat: How Deep Tech is Reshaping a More Human Future of Healthcare | LSI USA '26. Keynote: Bret Snyder CEO of W. L. Gore & Associates, and Lisa Carmel, Chair of Business Development, Mayo Clinic | LSI USA '26. Keynote: Mike Mahoney, CEO of Boston Scientific, and Peter Noseworthy, Mayo Clinic | LSI USA '26. Opening Fireside Chat with Omar Ishrak and Jean Nehme | LSI USA '26.
Device-Based Therapy for Hypertension: New Frontiers in Patient Care. Book Hotel with Discounted LSI Rates Before They're Gone. Defining the Debate in Soft Tissue Robotics. The Future of Soft Tissue Robotics: Open vs. Closed Systems. LSI USA ‘26 Registration FAQs. LSI USA ‘26 FAQs. Why the Clock Kills More Deals Than the Competition. John Wong, Fluid Biomed - Studio Interview | LSI USA '25. Kelly Huang, Elucid - Studio Interview | LSI USA '25. Signature Series: Unpacking Stryker's Acquisition of Artelon | LSI USA '25. Signature Series: No Corporate Slides. Real Strategies and Resources to Deliver Purpose-Driven AI | LSI USA '25.
What Works (and Doesn’t) in Build‑to‑Buy Deals in Medtech. The Best Practices Every Innovator Needs to Win in Medtech | LSI USA '25. Communicating Across Cultures: A Big Tech and Big Pharma Challenge. Thomas Nichols, Pretika MedTech - Studio Interview | LSI USA '25. Data, Complexity, and the Role of AI in Cardiovascular Imaging. What's Next for Renal Denervation? | LSI USA '25. A New Imperative for Cardiac Wearables: Inclusivity, Interoperability, and Insight. AI in Cardiovascular Imaging: Solving Complexity with Intelligence. Keynote with Joe Kiani, the Founder, Chairman, CEO of Willow Labs, and Founder of Masimo. A New Imperative for Cardiac Wearables: Inclusivity, Interoperability, and Insight. Big Tech and Big Pharma: How Medtech Can Bridge the Gap. The Next Frontier in Medical Robotics: Scaling Smarter. How to Build a Clear Path to Revenue that Attracts Investors and Acquirers.
Signature Series: Unlocking the Potential of Device-Based Hypertension Therapies. Understanding Corporate VCs’ Investment Criteria. Why Invest in Medtech and Healthtech in Africa? Keynote with Lisa Earnhardt, Executive Vice President & Group President, Medical Devices at Abbott. Device-Based Therapy for Hypertension: New Frontiers in Patient Care. Keynote with Gary S. Guthart, PhD, CEO and Member of the Board of Directors at Intuitive. Avitus Orthopaedics’ Acquisition: From Invention to Exit. Driving Medtech Market Access: Insights from cultivate(MD) At the LSI USA ’24 panel titled cultivate(MD): From the Kernel of an Idea to Harvesting an Exit, the team at cultivate(MD) and its portfolio companies showcased how they harness their network and expertise to accelerate growth and drive medtech market access.
Led by Dr. Sean Churchill, managing director of cultivate(MD), the discussion highlighted the power of collaboration and strategic insights in building successful ventures. With its physician-led team and extensive network, the fund has played a critical role in helping early-stage medtech companies navigate the path from concept to commercialization. The Power of Network-Driven Medtech Market Access David Blue, Chief Customer Experience Officer of Shoulder Innovations, shared how attending LSI USA changed the company’s trajectory.
“We pitched at this conference, and at the end of our presentation, a distinguished gentleman, who we later found out was Jonathan, gestured for us to follow him. Portfolio Companies Making an Impact. Prioritizing Patient-Centric Solutions: Insights from LSI USA ’24. As medtech innovations evolve, the emphasis has shifted from creating technology for technology’s sake to designing solutions that meet patients where they are. At LSI USA ’24, a diverse panel of medtech leaders, surgeons, and venture capitalists explored the theme of patient-centric solutions. The conversation highlighted how startups and established companies alike can reimagine their approaches to improve patient outcomes, enhance accessibility, and integrate seamlessly into the modern healthcare ecosystem. Lisa Carmel of Veranex moderated the panel, which included insights from Dr. Janani Reisenauer (Mayo Clinic), Amanda DePalma (Siemens Healthineers), Ashley Seehusen (Sante Ventures), and Dr.
Maria Artunduaga (Samay). Together, they tackled the challenges and opportunities of building solutions that put the patient first. The Evolution Toward Patient-Centric Solutions Dr. However, this patient-first model introduces new complexities. Overcoming Barriers to Patient Engagement. Medtech Venture Capital Decoded: Insider Tips from Top Investors.
Discover how clinical and regulatory strategies shape medtech success, from investment decisions to commercialization, as discussed at LSI USA ’24. Success in medtech innovation requires more than groundbreaking technology. During a panel at LSI USA ‘24, Ivanny Franklin of NAMSA emphasized the pivotal role of clinical and regulatory strategies in shaping investment decisions and driving long-term outcomes. Joined by distinguished panelists—Auriel August of Santé Ventures, Edwin Lindsay of Compliance Solutions Life Sciences, Nir Goldenberg of Mayo Clinic Ventures, and Adam Saltman of NAMSA—Franklin explored how regulatory rigor and clinical diligence intersect with investment value.
This blog dives into their insights, offering actionable advice for entrepreneurs and investors navigating this high-stakes landscape. Why Clinical and Regulatory Strategies Matter Medtech startups often focus on market potential, unmet clinical needs, and intellectual property when seeking funding. Yet, as Franklin observed, regulatory and clinical diligence is sometimes overlooked, creating significant risks: FDA Pathways: Understanding the Basics. Bioconvergence: Breaking Down Silos in Disruptive Innovation. Bioconvergence—the interdisciplinary fusion of biology, engineering, and technology—is redefining healthcare innovation.
This transformative approach was a central theme at LSI USA ‘24, where industry leaders shared insights into how bioconvergence is reshaping medical technologies, business models, and investment strategies. Here’s a deeper dive into key panel takeaways, highlighting its disruptive potential and the hurdles still to overcome. Defining Bioconvergence: A Multidisciplinary Solution Bioconvergence transcends traditional life sciences by integrating various scientific disciplines to tackle complex healthcare challenges. According to Assaf Barnea, Founder and Managing Partner of Sanara Ventures, “Bioconvergence is the convergence of biology with another domain related to engineering, such as software engineering or material science.” The concept is more than a buzzword; it represents a new paradigm for innovation. Challenges in Bioconvergence: Bridging Science and Business. Adoption of AR and VR in Healthcare: Tailwinds and Headwinds. At the LSI USA ‘24 Emerging Medtech Summit, industry leaders convened to discuss the burgeoning opportunities and persistent challenges of integrating AR and VR in healthcare.
The panel featured insights from Richard Vincent of FundamentalVR, Bhavesh Barot of Truffle Capital, and Rachel Van Stratton-Kirk of Johnson & Johnson MedTech, each bringing a unique perspective on the medtech market. Economic Constraints and Innovation Challenges The panel highlighted significant economic challenges that have slowed the adoption of innovative technologies in the medtech market. The macroeconomic environment over the past 18 months has led to major restructurings within organizations, impacting budget allocations and stifling innovation. “There isn’t one organization here that hasn’t had a major restructure—moved people around or out of the organization, restructured their budgets, and thought hard about where they spend.
Proof of Concept and Implementation Difficulties. Data-Driven Healthcare Solutions: Monetization and Adoptability. The LSI USA ‘24 Emerging Medtech Summit brought together leading minds in the industry to discuss the transformative power of data in healthcare. With the participation of industry leaders like Caitlin Morse, CEO of BrainSpace, and Peter Vranes, CEO of Nutromics, the panel provided valuable insights into how data can drive innovation and improve patient outcomes.
The discussions also highlighted the perspectives of medical device investors like David Kereiakes and David Cubbins, who offered their views on the economic aspects and investment potential of data-driven healthcare solutions. The Cornerstone of Data-Driven Healthcare Solutions: Actionable Data The panelists emphasized that for data to be valuable in the medtech market, it must drive actionable outcomes.
As Peter Vranes aptly said, “Data for data's sake is useless; it is a backward step. Enhancing Clinical Decision-Making with Data Monetizing Data: Challenges and Opportunities Building Trust Through Data Security Conclusion. Digital Technologies in Healthcare: Insights from Integra. Medtech Trends: Fireside Chat with Dave Hickey of BD Life Sciences. During a fireside chat at LSI USA ‘24, industry veteran Dave Hickey provided a wealth of insights into the dynamic and evolving medtech market. With over 40 years of experience, Hickey discussed transformative medtech trends, strategic partnerships, and the essential role of innovation in healthcare. Here are five key points from his talk, along with an overarching look at the medtech market's future. Embracing Smart Connected Care One of the foremost medtech trends highlighted by Dave Hickey is the increasing integration of automation, digitalization, and AI in healthcare. This trend aims to create more efficient "lights out" laboratories, where automated systems routine tasks, allowing medical staff to focus on more complex and value-added tasks.
“The demand is high for automation, track-based automation, and artificial intelligence to look at rules-based algorithms to disposition results and things of that nature. Migration to New Care Settings Addressing Chronic Disease Outcomes. Ambulatory Surgery Centers: The Role of Robotics. A panel at LSI USA ‘24 brought together industry leaders to discuss the rapidly evolving landscape of orthopedic surgery and the role of robotics in the growth of ambulatory surgery centers (ASCs). As the medtech market expands, these insights are invaluable for medical device investors and companies aiming to stay ahead of the curve. Here are six key points from the discussion that highlight the future direction of this dynamic field.
Open vs. Closed Robotic Systems A significant debate at the conference was whether robotic systems should be implant-specific or open to multiple implants. Stuart Simpson, CEO of THINK Surgical, emphasized the importance of flexibility: "You shouldn’t have to make those trade-off decisions—you should be able to independently choose the right technology and the right implant for all your patients. " This flexibility is particularly critical in ASCs, where surgeons often have varying preferences for implants.
Importance of Financial Efficiency in ASCs. Israel’s Medical Technology Ecosystem: A Culture of Innovation. Medtech Partnerships: How Can Major Device Companies Collaborate with the Startup Ecosystem? BCI Technologies: Neurotechnology to Address Limitations of the Human Body. At a panel at LSI USA '24, the discussion around brain-computer interfaces (BCIs) highlighted their transformative potential. BCI technologies, an emerging field within the medtech market, offer a promising path to restoring independence for individuals with motor impairments. This session, featuring experts Tom Oxley, CEO of Synchron, and Andy Rasdal, former CEO of Dexcom, provides insight into the intricacies of BCI technology, its market potential, and the strategic imperatives for success. Defining BCI Technologies BCIs are cutting-edge technologies that acquire and analyze brain signals, translating them into commands for output devices to perform desired actions.
"BCI is primarily a sensing technology. The Path to Commercialization The journey from concept to market is complex and demanding—particularly for novel medical technologies like BCIs. Funding and Investor Engagement Securing funding is a critical step for medtech startups. Regulatory Navigation Scaling Manufacturing. FDA Breakthrough Device Designation: ROI and Considerations With Shifts in Coverage. At a panel at LSI USA '24, industry experts gathered to share their perspectives on FDA Breakthrough Device Designation.
The panel included Lishan Aklog, CEO of Lucid Diagnostics; Nate Beaver, FDA Attorney at Foley & Lardner; Carolina Aguilar, Co-Founder and CEO of INBRAIN Neuroelectronics; and Kwame Ulmer, Managing Partner of MedTech Impact Partners. Their experiences highlight the strategic value and challenges of pursuing this designation. Understanding Breakthrough Device Designation Breakthrough Device Designation aims to accelerate the development and review process for medical devices that offer significant improvements over existing treatments for life-threatening or debilitating conditions. To qualify, devices must meet specific criteria, including providing a more effective treatment or diagnosis and offering significant advantages over existing alternatives. Nate Beaver explained the benefits: “You get more feedback, and you get it faster.
The Journey and Benefits Conclusion. Insights from LSI USA ‘24 | Investing for the Long-Haul: Supporting Companies and Aligning Investors Across Stages. Insights from LSI USA ‘24: What Does 2024 Hold For the Frozen IPO Market? As the medtech market evolves, companies looking to go public face unique challenges and opportunities. At a panel at LSI USA ‘24, industry experts shared their thoughts on preparing for an IPO, alternative financing strategies, and the importance of timing and stakeholder relationships.
Here are six key points discussed by the panelists. Current IPO Market Conditions The IPO market has seen a dramatic downturn in recent years, but there are signs of recovery. "We're coming out of a terrible IPO market. Alternative Financing Strategies With the IPO market's volatility, companies have sought alternative financing routes to sustain their operations and growth. "Over the past 12 to 18 months, we've been pushing hard to look for alternative funding sources—perhaps there’s government funding or organizations interested in supporting projects or companies. Preparing for an IPO Strategic timing and early preparation are crucial for a successful IPO. The Importance of a Strong Board Conclusion. Insights from LSI USA ‘24 | IP: Friend or Foe in Building Medtech Ventures? In a panel at LSI USA ‘24, experts shared their insights on how companies can effectively utilize IP to promote their innovations and navigate the competitive medtech market.
Here are six key takeaways from the discussion, highlighting the importance of IP strategy for innovators and medical device investors. The Value of Patents in Attracting Investment Patents are crucial for securing investments, especially for early-stage companies in the medtech market. A robust patent portfolio demonstrates the uniqueness and protectability of a company's innovations, significantly influencing investors' decisions. Importance of Comprehensive and Early Patent Filings Early and comprehensive patent filings are essential for protecting evolving designs and securing investor confidence. Filing provisional patents early on helps establish a priority date and safeguards innovations as they develop. "Early-stage companies need to have provisionals on file as they get a little bit further along. Conclusion. The Memo: Flow Medical Creating the New Standard of Care for Interventional PE Treatment. Under the direction of CEO and Co-Founder Jennifer Fried, Flow Medical is creating the new standard of care for interventional pulmonary embolism (PE) treatment.
The company is developing the next generation of thrombolysis catheters to address shortcomings of current devices, such as imprecise lytic dosing and lack of access to small distal vessels. Origin Story Flow Medical originated in the heart of the University of Chicago’s Medical Center. The company’s innovators were Dr. Jonathan Paul, an interventional cardiologist, and Dr. The turning point came in 2020 with the onset of the COVID-19 pandemic, which led to a surge in pulmonary complications and an increase in PE cases. Seeing a significant gap in treatment, they decided to “create a next-generation thrombolysis catheter.” The Current Landscape 600,000 VTE events occur in the United States. One of the primary issues lies in the treatment landscape. Inside the Innovation Progress and Milestones Market Insights Join Us at LSI USA ‘25. The Weekly Recap 10/04/24: LSI Alumni Achievements Driving Medtech and Healthtech Forward.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory clearance, secure new funding and contracts, enter strategic partnerships, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21). Access Vascular Presented new data showing that its HydroMID® midline catheter significantly reduced complications compared to a conventional CHG-coated catheter. The HydroMID catheter had a 95% therapy completion rate and a lower complication rate of 5%, outperforming the CHG catheter, despite longer dwell times.
Amsel Medical Received a $7.45M sole-source, non-dilutive small business innovation research (SBIR) Phase III contract from the United States Air Force. Elucid Received FDA 510(k) clearance for its PlaqueIQ™ imaging analysis software to aid in the diagnosis of cardiovascular disease. Greenlight Guru & Alpha Sophia LSI Alumni Alpha Sophia and Greenlight Guru entered a strategic partnership. Insights from LSI USA '24: The Verticalization of AI in Medtech and Healthcare.
The medtech market is experiencing a transformative shift with the integration of AI technologies in healthcare. At a panel at LSI USA ‘24, industry leaders discussed the rapid evolution of AI, its challenges, and the opportunities it brings. Here are six key points from the discussion, highlighting the implications for medical device investors and the broader healthcare industry. The Rapid Evolution of AI Technologies in Healthcare AI technologies in healthcare have swiftly moved from being experimental to becoming essential tools.
This shift is particularly evident in areas like automatic transcription and radiology, where recent advancements have made previously unreliable technologies highly effective. The exponential growth in AI capabilities has created a fertile ground for innovation, allowing new solutions to rapidly enter the market and improve administrative efficiency and patient care. Challenges in Adoption and Differentiation Clinician Engagement and Trust Conclusion. Insights from LSI USA '24: The Agony and Ecstasy of Doing Big Things in Medtech. Insights from LSI USA ‘24: Palette Life Sciences, Financial and Transactional Insight on Their $600M+ Exit With Teleflex. Insights from LSI USA ‘24: Medtech Buyouts by Private Equity. Insights From LSI USA ‘24: Medtech M&A 2024, Looking Onward and Upward. Insights From LSI USA ‘24: Bridging the Gap Between Academia and Industry.
Insights From LSI USA ‘24: Medtech Growth Capital and the New Normal in Late-Stage Financing.